We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App





Quidel Granted FDA EUA for Lyra Direct SARS-CoV-2 Assay to Allow Direct Sample Processing

By HospiMedica International staff writers
Posted on 20 May 2020
Quidel Corporation (San Diego, CA, USA) has received Emergency Use Authorization (EUA) for the Lyra Direct SARS-CoV-2 Assay from the Food and Drug Administration (FDA) to allow direct sample processing.

Under the new EUA, the Lyra Direct SARS-CoV-2 Assay no longer requires an up-front sample extraction. More...
The Lyra Direct SARS-CoV-2 Assay uses a reformulated buffer that replaces the extraction step with a simple 10-minute heat step, saving approximately 50 minutes in processing time. The assay retains its versatility in that it is capable of running on any of seven possible thermocyclers (Applied Biosystems 7500 Standard, Applied Biosystems 7500 Fast, Bio-Rad CFX96 Touch, Qiagen Rotor-Gene Q, Roche LightCycler 480, Roche Cobas z480, and Thermo Fisher QuantStudio 7 Pro).

Separately, the Lyra Direct SARS-CoV-2 Assay received CE Mark on May 8, 2020. The CE Mark allows Quidel to market and sell the Lyra Direct SARS-CoV-2 Assay in Europe, as well as other countries that accept the CE Mark. The assay is currently available for sale in the US under EUA.



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Hypodermic Syringe
SurTract™ Safety Syringe
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
image: Principles of SMEAR-ULM. (Lai, Y., Argüello, A.N., Liu, M. et al., Nature Sensors (2026). DOI: 10.1038/s44460-026-00078-4)

“Intelligent Tattoo” Method Detects Early Melanoma Signals

Melanoma is a lethal skin cancer in which earlier detection drives better outcomes. Current evaluation relies on visual inspection followed by biopsy, which can miss nascent lesions and lead to unnecessary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.